Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron PK Study in Healthy Adults
NCT06153758Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (Fasted), Maximum Observed Concentration (Fasted) and 3 more. Started Nov 2023; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06153758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153758.